Avatar

Share this article:

Join our newsletter to stay up-to-date with the latest insights in biotechnology!

Engineering bispecific antibodies

Recorded Presentation: From mAb to bAb

Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production can help you engineer, reformat, and produce your therapeutic, using a case study for the transformation of a mAb into a bsAb.

Engineering bispecific antibodies – video

Request presentation record

Speaker

Desmond Schofield
evitria AG
Chief Business Officer

As Chief Business Officer, Desmond Schofield leads strategic initiatives focused on fostering growth and innovation. His responsibilities include crafting and implementing strategies to enhance customer service and satisfaction within a constantly evolving market.

Learn more


How to choose a bispecific antibody format

Bispecific antibody production – a comprehensive overview

bYlok® bispecific pairing technology in bsAb production

Avatar

Written by Desmond Schofield Follow on linkedin

Read more from Desmond Schofield

Further readings about News

  • Engineering bispecific antibodies

    Recorded Presentation: From mAb to bAb Developing drugs requires navigating complex technical, practical, and strategic challenges quickly. Optimizing a drug’s activity and effectiveness and subsequently considering the IP landscape are crucially important balancing acts. Here, we demonstrate how evitria’s extensive expertise in antibody production can help you engineer, reformat, and produce your therapeutic, using a […]

    Avatar
  • Bispecific Antibodies: Commercial Successes and Research Feasibility

    In the past 10 years, the use of bispecific antibodies – proteins capable of engaging two targets simultaneously – has become a key focus area for the industry. Read all about their success and research feasibility in this article.

    Avatar